title: Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
abstract: In recent years, heterologous prime-boost vaccines have been demonstrated to be an effective strategy for generating protective immunity, consisting of both humoral and cell-mediated immune responses against a variety of pathogens including HIV-1. Previous reports of preclinical and clinical studies have shown the enhanced immunogenicity of viral vector or DNA vaccination followed by heterologous protein boost, compared to using either prime or boost components alone. With such approaches, the selection of an adjuvant for inclusion in the protein boost component is expected to impact the immunogenicity and safety of a vaccine. In this study, we examined in a mouse model the serum cytokine and chemokine profiles for several candidate adjuvants: QS-21, Al(OH)3, monophosphoryl lipid A (MPLA) and ISCOMATRIX™ adjuvant, in the context of a previously tested pentavalent HIV-1 Env DNA prime-protein boost formulation, DP6-001. Our data revealed that the candidate adjuvants in the context of the DP6-001 formulation are characterized by unique serum cytokine and chemokine profiles. Such information will provide valuable guidance in the selection of an adjuvant for future AIDS vaccine development, with the ultimate goal of enhancing immunogenicity while minimizing reactogenicity associated with the use of an adjuvant. More significantly, results reported here will add to the knowledge on how to include an adjuvant in the context of a heterologous prime-protein boost vaccination strategy in general.
authors.affiliation: Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
authors.forename: Rachel
authors.initials: R
authors.lastname: Buglione-Corbett
authors.forename: Kimberly
authors.initials: K
authors.lastname: Pouliot
authors.forename: Robyn
authors.initials: R
authors.lastname: Marty-Roix
authors.forename: Kim
authors.initials: K
authors.lastname: West
authors.forename: Shixia
authors.initials: S
authors.lastname: Wang
authors.forename: Egil
authors.initials: E
authors.lastname: Lien
authors.forename: Shan
authors.initials: S
authors.lastname: Lu
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D016207:Cytokines / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D013601:T-Lymphocytes / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D019444:Vaccines, DNA
references.citation: AIDS Res Hum Retroviruses. 2005 Feb;21(2):165-70
references.pmid: 15725756
references.citation: Cancer Immunol Immunother. 2011 Nov;60(11):1625-37
references.pmid: 21698545
references.citation: J Med Primatol. 2005 Oct;34(5-6):226-36
references.pmid: 16128917
references.citation: J Med Microbiol. 2012 Jul;61(Pt 7):935-943
references.pmid: 22442293
references.citation: Trends Immunol. 2003 Jan;24(1):25-9
references.pmid: 12495721
references.citation: Immunol Today. 1995 Jan;16(1):21-6
references.pmid: 7880385
references.citation: Hum Vaccin. 2010 Mar 30;6(3):
references.pmid: 20595811
references.citation: Immunol Rev. 2000 Oct;177:195-203
references.pmid: 11138776
references.citation: Nat Rev Microbiol. 2007 Jul;5(7):505-17
references.pmid: 17558426
references.citation: AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1163-77
references.pmid: 9310283
references.citation: Immunity. 2001 Jun;14(6):705-14
references.pmid: 11420041
references.citation: Vaccine. 2010 Apr 9;28(17):2999-3007
references.pmid: 20170767
references.citation: Int Arch Allergy Immunol. 1996 Apr;109(4):301-7
references.pmid: 8634513
references.citation: N Engl J Med. 2012 Dec 13;367(24):2284-95
references.pmid: 23136909
references.citation: J Leukoc Biol. 2005 Dec;78(6):1273-80
references.pmid: 16204643
references.citation: Clin Cancer Res. 2004 Apr 15;10(8):2879-90
references.pmid: 15102697
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702
references.pmid: 15252201
references.citation: Cell Immunol. 1997 Apr 10;177(1):69-76
references.pmid: 9140097
references.citation: Vaccine. 2004 Nov 25;23(2):172-81
references.pmid: 15531034
references.citation: J Infect Dis. 2012 Aug 1;206(3):431-41
references.pmid: 22634875
references.citation: J Immunol. 1996 Jan 1;156(1):389-94
references.pmid: 8598489
references.citation: Vaccine. 2008 Feb 20;26(8):1098-110
references.pmid: 18243434
references.citation: Vaccine. 2001 Feb 28;19(15-16):2080-91
references.pmid: 11228380
references.citation: J Immunol. 2011 Jul 1;187(1):55-63
references.pmid: 21613613
references.citation: Exp Dermatol. 2009 Jan;18(1):91-6
references.pmid: 18803657
references.citation: J Leukoc Biol. 1999 May;65(5):671-9
references.pmid: 10331497
references.citation: Vaccine. 2001 Mar 21;19(17-19):2661-5
references.pmid: 11257406
references.citation: Vaccine. 2008 Aug 18;26(35):4420-4
references.pmid: 18588934
references.citation: Curr Opin Immunol. 2009 Feb;21(1):23-9
references.pmid: 19246182
references.citation: J Immunol. 2005 Sep 15;175(6):3463-8
references.pmid: 16148087
references.citation: N Engl J Med. 2009 Dec 3;361(23):2209-20
references.pmid: 19843557
references.citation: Hum Vaccin. 2009 Mar;5(3):151-7
references.pmid: 19246990
references.citation: Immunol Cell Biol. 2005 Apr;83(2):119-28
references.pmid: 15748208
references.citation: Immunol Cell Biol. 2009 Jul;87(5):371-6
references.pmid: 19381160
references.citation: Science. 2007 Jun 15;316(5831):1628-32
references.pmid: 17569868
references.citation: Virology. 2006 Mar 1;346(1):151-68
references.pmid: 16325880
references.citation: Nat Rev Immunol. 2009 Apr;9(4):287-93
references.pmid: 19247370
references.citation: Virology. 2006 May 10;348(2):341-53
references.pmid: 16460776
references.citation: Vaccine. 2004 Jun 23;22(19):2391-5
references.pmid: 15193400
references.citation: J Immunol. 2012 May 15;188(10):5166-76
references.pmid: 22529301
references.citation: J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):371-81
references.pmid: 19661810
references.citation: J Virol. 2008 Jul;82(13):6458-69
references.pmid: 18448544
references.citation: PLoS One. 2011;6(12):e27837
references.pmid: 22205930
references.citation: Vaccine. 2007 Mar 30;25(14):2541-4
references.pmid: 17240491
references.citation: Immunol Cell Biol. 2012 May;90(5):540-52
references.pmid: 21894173
references.citation: Vaccine. 2006 Feb 20;24(8):1225-34
references.pmid: 16219399
references.citation: Vaccine. 2008 Jun 6;26(24):3036-45
references.pmid: 18226433